MAY 07, 2015 02:21 PM PDT

Personal Profiling for Womb Cancer

About 2.8 percent of women will be diagnosed with endometrial cancer at some point in their lives, according to the National Cancer Institute. Contributing factors to the disease, in which malignant cells form in the tissues of the endometrium, include hormone therapy, obesity, high blood pressure and diabetes mellitus (http://seer.cancer.gov/statfacts/html/corp.html).
Genetic profiling of endometrial cancer can lead to more effective treatment.
The American Cancer Society says that cancer of the endometrium - the lining of the uterus or womb -- is the most common cancer of the female reproductive organs. The organization projects that in 2015 approximately 54,870 new cases of cancer of the body of the uterus (uterine body or corpus, including the endometrium) will be diagnosed, and 10,170 women will die from such cancers (http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-what-is-endometrial-cancer ).

Until now patients with endometrial cancer were classified as to their risk of disease in terms of a combination of clinical and tissue characteristics, such as their age, overall health data and the "growth and invasion of their tumor," according to researchers at the University of Manchester. Now these researchers can genetically profile high-risk womb cancer patients, enabling the patients to receive more appropriate treatment (University of Manchester. "Potential for a more personalized approach to womb cancer." ScienceDaily. ScienceDaily, 7 May 2015; www.sciencedaily.com/releases/2015/05/150507081741.htm).

While approximately 15 to 20 percent of endometrial cancer patients have high-risk disease, the optimal treatment approach for them has not been evident. The Manchester researchers have been studying genetic alterations in high-risk endometrial cancer, to determine whether they could be used to develop tumor subtypes. The team included Professor Richard Edmondson, Professor of Gynecological Oncology at The University of Manchester and Saint Mary's Hospital, as well as Dr Emma Crosbie and Professor Henry Kitchener from Manchester.

According to Prof. Edmondson, "Previous work, using comprehensive genetic profiling, has suggested that endometrial cancer can be classified into four subtypes. Our study has explored whether it is possible to use a simpler approach to detect subgroups in high risk patients."

Analyzing samples from 116 patients with endometrial cancer to find genetic variations, the international TransPORTEC research consortium discovered that genetic subtypes existed in their group of patients and that the classification procedure could predict which patients were more likely to relapse. The analysis enabled the researchers to identify distinctive genetic mutations that they could target with specific anti-cancer drugs.

Prof. Edmondson concluded, "It looks like these cancers classed as 'high-risk' in fact vary significantly in outcome. Our results could be used to refine risk assessment for endometrial cancer patients and allow doctors to choose either a less aggressive approach or more targeted treatment for individual patients." (University of Manchester. "Potential for a more personalized approach to womb cancer." ScienceDaily. ScienceDaily, 7 May 2015. www.sciencedaily.com/releases/2015/05/150507081741.htm).

Source: University of Manchester
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
OCT 16, 2019
Cancer
OCT 16, 2019
An Ointment to Stop Skin Cancer Growth
Russian scientists are developing an ointment to undermine the growth of skin cancer, according to a review recently published in Molecules. One in three c...
OCT 16, 2019
Immunology
OCT 16, 2019
Are Bacteria Fighting Cancer For Us?
Scientists at the Sanford Burnham Prebys Medical Discovery Institute found that the RNF5 enzyme, produced by a gene in gut microbes affects tumor growth.&n...
OCT 16, 2019
Cancer
OCT 16, 2019
New method to stop metastasis in lymph nodes
Research reported recently in ACS Nano explains a new method of targeting metastases in lymph nodes as a means of preventing the spread of cancers. The app...
OCT 16, 2019
Drug Discovery & Development
OCT 16, 2019
Comparison of Three Frontline Breast Cancer Drugs
Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 r...
OCT 16, 2019
Cancer
OCT 16, 2019
Urine test detects cancer: watch out for blue pee!
New research from MIT engineers and Imperial and published in Nature Nanotechnology could change the way to detect cancer. The study highlights the develop...
OCT 16, 2019
Cancer
OCT 16, 2019
Cancer drugs don't work the way we thought
New research recently published in the journal Science Translational Medicine surprises the oncological community with findings that a protein previously t...
Loading Comments...